2024 - Announcements and Circulars - INVESTORS - Laekna

INVESTOR RELATIONS

CURE FOR A BETTER FUTURE

Scroll down to see more

Announcements and Circulars

2025 2024 2023

May 23, 2024

[VOLUNTARY ANNOUNCEMENT] - APPROVAL BY THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE PHASE III
CLINICAL TRIAL PROTOCOL OF LAE002 (AFURESERTIB) PLUS LAE001 FOR THE TREATMENT OF PROSTATE CANCER
More
May 22, 2024

[Proxy Forms] - PROXY FORM FOR THE ANNUAL GENERAL MEETING
More
May 22, 2024

[Notice of AGM / Closure of Books or Change of Book Closure Period] - NOTICE OF ANNUAL GENERAL MEETING
More
May 22, 2024

[Re-election or Appointment of Director subject to Shareholders' Approval / General Mandate / Explanatory Statement for Repurchase of Shares / Share Scheme] - PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITOR; PROPOSED ADOPTION OF THE SHARE AWARD SCHEME; AND NOTICE OF ANNUAL GENERAL MEETING
More
May 21, 2024

[Share Scheme] - PROPOSED ADOPTION OF THE SHARE AWARD SCHEME
More
May 10, 2024

[VOLUNTARY ANNOUNCEMENT] - INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE102 FOR THE TREATMENT OF OBESITY WAS OBTAINED FROM THE CENTRE FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA
More

<1 2 3 4 5 6 7 8 >

RSS Feeds

If you want to know more about Laekna, please fill in the form below and sign up for emails:

Follow us on Linkedin

Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号 Privacy Policy

Follow us on Linkedin

Follow us on Wechat